Lap-Band System
Commercial- Indications
- Obesity
Company intelligence / Profile preview
ReShape Lifesciences has commercialized minimally invasive weight-loss devices such as the FDA-approved Lap-Band®, the non-surgical Obalon® Gastric Balloon system, and offers a virtual health coaching program. The company also developed an investigational vagal neuromodulation technology for type 2 diabetes that has completed preclinical development with strong IP protection through at least the late 2030s. In Q2/Q3 of calendar year 2025, ReShape entered into a definitive merger agreement with Vyome Therapeutics and agreed to sell substantially all its assets—including its core products—to Biorad Medisys. After these transactions close, the combined entity will be renamed Vyome Holdings.
2 more assets in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on ReShape Lifesciences.